SMI Semiconductor Manufacturing International Corp. Adr

¹   Consists of (i) 797,054,901 shares of common stock, par value US$0.004 each, of Semiconductor Manufacturing International Corporation (the “Common Stock”); and (ii)183,178,403 shares of Common Stock assuming the full conversion of the China IC Fund PSCS (as defined below) based on the initial conversion price.

 

²   This calculation is rounded to the nearest tenth and is based on 5,051,716,327 shares of Common Stock of the Issuer outstanding as of August 29, 2018 and 344,985,992 shares of Common Stock assuming full conversion of all of the PSCS issued by the Issuer based on the initial conversion price.

 

---

 

 

---

⁵   Consists of 797,054,901 shares of common stock, par value US$0.004 each share   and (ii)183,178,403 shares of Common Stock assuming the full conversion of the China IC Fund PSCS based on the initial conversion price.

 

⁶   This calculation is rounded to the nearest tenth and is based on 5,051,716,327 shares of Common Stock of the Issuer outstanding as of August 29, 2018 and 344,985,992 shares of Common Stock assuming full conversion of all of the PSCS issued by the Issuer based on the initial conversion price.

 

---

Item 1.   Security and Issuer

 

This Amendment No. 2 (this “Amendment”) amends the Schedule 13D jointly filed with the Securities and Exchange Commission (the “ SEC ”) on May 8, 2017 and the Amendment No.1 filed on May 18, 2018, with respect to the common stock, par value US$0.004 per share (the “ Common Stock ”) of Semiconductor Manufacturing International Corporation (“ SMIC ” or the “ Issuer ”), a company incorporated in the Cayman Islands, having its principal executive offices at 18 Zhangjiang Road, Pudong New Area, Shanghai 201203, People’s Republic of China.

 

Item 2.  Identity and Background

 

The Item 2 is hereby amended in its entirety as follows:

 

(a) — (c); (f) This Amendment is being filed by (i) China Integrated Circuit Industry Investment Fund Co., Ltd., a company organized under the laws of the People’s Republic of China (“ China IC Fund ”); (ii) Xunxin (Shanghai) Capital Co., Limited, a company organized under the laws of the People’s Republic of China (the “Xunxin”); and (iii) Xinxin (HongKong) Capital Co., Limited, a company organized under the laws of Hong Kong (the “ HKCo ”).  China IC Fund, Xunxin and HKCo are hereinafter referred to, collectively the “ Reporting Persons ” and each a “ Reporting Person .”  Each of the Reporting Persons is a party to the Joint Filing Agreement, as further described in Item 6.  Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D. China IC Fund’s principal office address is Room 718, 7/F, Block 52, No. 2 Jingyuan North Street, Economic and Technological Development Area, Beijing, People’s Republic of China.  The principal business of China IC Fund is investment in the integrated circuit industry, primarily in chip manufacturing, designing, packaging test, equipment and materials.  Xunxin’s principal office address is 10/F and 11/F, No. 60 Mudan Road, Pudong New Area, Shanghai, People’s Republic of China. Xunxin’s principal business is investment holdings and administration.  HKCo’s principal office address is Flat A 20/F, Kiufu Commercial Building, 300 Lockhart Road, Wan Chai, Hong Kong. The principal business of HKCo is investment holdings.

 

Schedule A below lists the executive officers and directors of China IC Fund and contains the information concerning each person including: (i) name; (ii) business address; (iii) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (iv) citizenship:

 

Schedule A

 

CUSIP No. 81663 N206

SCHEDULE 13D

 

(d) — (e) During the past five years, neither China IC Fund nor, to the best of its knowledge, any person named in Schedule A above, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Schedule B below lists the executive officers and directors of Xunxin and contains the information concerning each person including: (i) name; (ii) business address; (iii) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (iv) citizenship:

 

Schedule B

 

(d) — (e) During the past five years, neither Xunxin nor, to the best of its knowledge, any person named in Schedule B above, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Schedule C below lists the executive officers and directors of HKCo and contains the information concerning each person including: (i) name; (ii) business address; (iii) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (iv) citizenship:

 

Schedule C

 

(d) — (e) During the past five years, neither HKCo nor, to the best of its knowledge, any person named in Schedule C above, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

CUSIP No. 81663 N206

SCHEDULE 13D

 

Item 3.  Source and Amount of Funds or Other Consideration

 

The Item 3 is hereby amended in its entirety as follows:

 

On February 12, 2015, China IC Fund and SMIC entered into a share purchase agreement (the “2015 SPA ”), pursuant to which, subject to the terms and conditions of the agreement, SMIC agreed to issue to China IC Fund, and China IC Fund agreed to subscribe from SMIC, 4,700,000,000 shares of Common Stock of SMIC at the purchase price of HK$ 0.6593 per share, totaling HK$3,098,710,000. This transaction was closed on June 8, 2015 and whereby China IC Fund, via HKCo, acquired the said shares, representing approximately 11.6% of the issued share capital of SMIC.

 

On October 14, 2015, China IC Fund and Country Hill Limited, a wholly-owned subsidiary of China Investment Corporation, entered into a share purchase agreement (the “ CIC SPA ”), pursuant to which, Country Hill Limited agreed to sell, and China IC Fund agreed to purchase, 2,700,000,000 shares of Common Stock at the purchase price of HKD 0.75 per share, totaling HK$2,025,000,000.  This transaction was closed on December 28, 2015.  Upon closing of the transaction, China IC Fund, via HKCo, held an aggregate of 7,400,000,000 shares of Common Stock, representing 17.7% of the issued share capital of SMIC.

 

Both of the subscription of the 4,700,000,000 shares from SMIC and the purchase of 2,700,000,000 shares from Country Hill Limited were funded by China IC Fund’s own working capital.

 

In December 2016, as a result of the Issuer’s consolidation of every 10 shares of its Common Stock into one share of Common Stock, the number of shares held by HKCo was changed from 7,400,000,000 to 740,000,000.

 

Following the subscription under the 2015 SPA and the purchase of shares under the CIC SPA, the Issuer’s total issued and outstanding Common Stock increased as a result of the exercising of certain stock options and conversion of certain convertible bonds into Common Stock, which caused the percentage of shares held by HKCo to become 15.9% as of April 27, 2017.

 

On December 6, 2017, pursuant to a placing agreement, dated November 29, 2017, entered into by and among the Issuer, J.P. Morgan Securities plc and Deutsche Bank AG, Hong Kong Branch, as joint placing agents, the Issuer issued 241,418,625 ordinary shares to certain third party investors, representing approximately 4.92% of the issued share capital of the Issuer as enlarged by the issue, at the price of HK$10.65 per share.  On December 14, 2017, pursuant to a perpetual subordinated convertible securities subscription agreement, dated November 29, 2017, entered into by and among the Issuer and Barclays Bank PLC, Deutsche Bank AG, Hong Kong Branch and J.P. Morgan Securities Plc, as joint managers, the Issuer issued perpetual subordinated convertible securities (“PSCS”) to certain third party investors in the aggregate principal amount of US$65 million.  As a result, the shareholding of the Reporting Persons in the Issuer was diluted from approximately 15.9% to approximately 15.0%.

 

On April 23 2018, pursuant to the pre-emptive right under the 2015 SPA, China IC Fund, HKCo and the Issuer entered into a share subscription agreement (the “2018 SPA”) and a PSCS subscription agreement (“PSCS Subscription Agreement”).  Pursuant to the 2018 SPA, the Issuer conditionally agreed to issue, and China IC Fund, through HKCo, conditionally agreed to subscribe for, 57,054,901 shares of Common Stock of the Issuer, representing approximately 1.16% of the total issued share capital of the Issuer as at the date of 2018 SPA, for a cash consideration of HK$10.65 per share, totaling HK$607,634,695.65.  Pursuant to the PSCS Subscription Agreement, the Issuer conditionally agreed to issue, and China IC Fund, through HKCo, conditionally agreed to subscribe for, the PSCS in an aggregate principal amount of US$300 million for a total cash consideration of US$300 million (“China IC Fund PSCS”). The China IC Fund PSCS are convertible into 183,178,403 shares of Common Stock of the Issuer, representing approximately 3.58% of the issued share capital of the Issuer as enlarged by and assuming full conversion of the China IC Fund PSCS. The conversion price is HK$12.78 per share, subject to adjustment. The 2018 SPA and the PSCS Subscription Agreement were closed on August 29, 2018. The purchase prices under the 2018 SPA and the PSCS Subscription Agreement were paid out of the working capital of HKCo.

 

CUSIP No. 81663 N206

SCHEDULE 13D

 

Other than the transactions as described in this Item 3 above, none of the Reporting Persons nor, to their best knowledge, any of the persons set forth on Schedule A , Schedule B and Schedule C above, has effected any transaction in the Common Stock.

 

The description of the 2015 SPA, the CIC SPA, the 2018 SPA and the PSCS Subscription Agreement is a summary and is qualified in its entirety by the terms of such agreements, copies of which are attached hereto as Exhibits 1, 2, 4 and 5, respectively.

 

Item 4.  Purpose of Transaction

 

Item 4 is hereby amended in its entirety as follows:

 

The information set forth in Item 3 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4.

 

The Reporting Persons may further purchase, hold, vote, trade, dispose or otherwise deal in the Common Stock and/or PSCS at times, and in such manner, as they deem advisable, subject to applicable law, to benefit from changes in market prices of such Common Stock, changes in the Issuer’s operations, business strategy or prospects, or from sale or merger of the Issuer.  To evaluate such alternatives, the Reporting Persons will routinely monitor the Issuer’s operations, prospects, business development, management, competitive and strategic matters, capital structure, and prevailing market conditions, as well as other investment considerations. Consistent with its investment research methods and evaluation criteria, the Reporting Persons may discuss such matters with management or directors of the Issuer, other shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other investors.  Such factors and discussions may materially affect, and result in, subject to the limitations set forth in applicable law, the Reporting Persons’ modifying their ownership of the Common Stock, exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements, proposing changes in the Issuer’s operations, governance or capitalization, or pursuing one or more of the other actions described in subsections (a) through (j) of the instructions under Item 4 of Schedule 13D.

 

Item 5.  Interest in Securities of the Issuer

 

Item 5 is hereby amended in its entirety as follows:

 

(a) — (b) As of the date of this Schedule 13D, China IC Fund may be deemed to have (i) beneficial ownership and (ii) shared power with Xunxin and HKCo to vote or direct to vote, and shared power with Xunxin and HKCo to dispose or direct disposition of, 980,233,304 shares of Common Stock, representing 18.2% of the outstanding Common Stock of SMIC on an as-converted basis.  China IC Fund may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer because HKCo, the record owner of the Common Stock, is China IC fund’s indirect wholly-owned subsidiary.

 

As of the date of this Schedule 13D, Xunxin may be deemed to have (i) beneficial ownership and (ii) shared power with China IC Fund and HKCo to vote or direct to vote, and shared power with China IC Fund and HKCo to dispose or direct disposition of, 980,233,304 shares of Common Stock, representing 18.2% of the outstanding Common Stock of SMIC on an as-converted basis.  Xunxin may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer because HKCo, the record owner of the Common Stock, is Xunxin’ wholly-owned subsidiary.

 

CUSIP No. 81663 N206

SCHEDULE 13D

 

As of the date of this Schedule 13D, HKCo may be deemed to have (i) beneficial ownership and (ii) shared power with China IC Fund and Xunxin to vote or direct to vote, and shared power with China IC Fund and Xunxin to dispose or direct disposition of, 980,233,304 shares of Common Stock, representing 18.2% of the outstanding Common Stock on an as-converted basis.  HKCo may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer because HKCo is the record owner of the Common Stock.

 

(c) Other than the transactions as described in Item 3 above, none of the Reporting Persons nor, to their best knowledge, any of the persons set forth on Schedule A,   Schedule B and Schedule C above, has effected any transaction in Common Stock during the past sixty (60) days.

 

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares beneficially owned by the Reporting Persons.

 

(e) Not applicable.

 

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities

 

Item 6 is hereby amended in its entirety as follows:

 

The information disclosed in Items 3 through 5 above is incorporated herein by reference.

 

Pursuant to Rule 13d-1(k), the Reporting Persons have entered into an agreement, attached hereto as Exhibit 3, with respect to the joint filing of this Schedule 13D and any amendment or amendments hereto.

CUSIP No. 81663 N206

SCHEDULE 13D

 

Item 7.  Material to be Filed as Exhibits

 

 

CUSIP No. 81663 N206

SCHEDULE 13D

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

 

Date:  August 31, 2018	China Integrated Circuit Industry Investment Fund Co., Ltd.
	By:	/s/ Wang Zhanfu
	Name:	Wang Zhanfu
	Title:	Authorized Representative
	Xunxin (Shanghai) Capital Co., Limited
	By:	/s/ Wu Fengshuo
	Name:	Wu Fengshuo
	Title:	Authorized Representative
	Xinxin (HongKong) Capital Co., Limited
	By:	/s/ Wu Fengshuo
	Name:	Wu Fengshuo
	Title:	Authorized Representative

 

 

---